Skip to main content

Table 1 Association of MACC1 SNPs with clinicopathological factors

From: SNPs in the coding region of the metastasis-inducing gene MACC1 and clinical outcome in colorectal cancer

rs4721888 (L31V)

     

Parameters

Leu/Leu (ctc/ctc) (%)

Leu/Val (ctc/gtc) (%)

P-value

OR

95% CI

All tumors, n = 154

134 (87%)

20 (13%)

   

Metachronous metastasis,n = 29

27 (93%)

2 (7%)

0.28

0.44

0.10 - 2.02

Gender male, n = 79

68 (86%)

11 (14%)

0.72

1.19

0.46 - 3.05

Age > 66.32 years (median),n = 77

67 (87%)

10 (13%)

1.00

1.00

0.39 – 2.56

pT3 and pT4, n = 118

102 (86%)

16 (14%)

0.70

1.26

0.39 - 4.03

N1 to N3, n = 53

43 (81%)

10 (19%)

0.12

2.12

0.82 - 5.47

UICC stage I, n = 26

24 (92%)

2 (8%)

0.38

0.51

0.11 - 2.34

UICC stage II, n = 74

66 (89%)

8 (11%)

0.44

0.69

0.26 - 1.79

UICC stage III, n = 54

44 (81%)

10 (19%)

0.13

2.05

0.79 - 5.28

rs975263 (S515L)

     

Parameters

Ser/Ser (tcg/tcg) (%)

Ser/Leu (tcg/ttg) (%)

P-value

OR

95% CI

All tumors, n = 154

80 (52%)

74 (48%)

   

Metachronous metastasis,n = 29

12 (41%)

17 (59%)

0.21

1.69

0.75 – 3.83

Gender male, n = 79

40 (51%)

39 (49%)

0.74

1.11

0.59 - 2.10

Age > 66.32 years (median),n = 77

40 (52%)

37 (48%)

1.00

1.00

0.53 – 1.88

pT3 and pT4, n = 118

63 (53%)

55 (47%)

0.52

0.78

0.37 - 1.65

N1 to N3, n = 53

26 (49%)

27 (51%)

0.60

1.19

0.61 - 2.32

UICC stage I, n = 26

14 (54%)

12 (46%)

0.83

0.91

0.39 - 2.13

UICC stage II, n = 74

39 (53%)

35 (47%)

0.86

0.94

0.50 - 1.78

UICC stage III, n = 54

27 (50%)

27 (50%)

0.72

1.13

0.58 - 2.19

rs3735615 (R804T)

   

without R804T compared to with R804T

Parameters

Arg/Arg (aga/aga) (%)

Arg/Thr (aga/aca) (%)

Thr/Thr (aca/aca) (%)

P-value

OR

95% CI

All tumors, n = 154

25 (16%)

74 (48%)

55 (36%)

   

Metachronous metastasis,n = 29

5 (17%)

15 (52%)

9 (31%)

0.95

0.96

0.33 - 2.80

Gender male, n = 79

11 (14%)

37 (47%)

31 (39%)

0.43

1.42

0.60 - 3.36

Age > 66.32 years (median),n = 77

12 (16%)

39 (51%)

26 (34%)

0.83

1.10

0.47 - 2.59

pT3 and pT4, n = 118

21 (18%)

53 (45%)

44 (37%)

0.34

0.58

0.18 - 1.81

N1 to N3, n = 53

9 (17%)

27 (51%)

17 (32%)

0.86

0.92

0.38 - 2.25

UICC stage I, n = 26

4 (15%)

14 (54%)

8 (31%)

0.90

1.08

0.34 - 3.46

UICC stage II, n = 74

12 (16%)

32 (43%)

30 (41%)

1.00

1.00

0.43 - 2.36

UICC stage III, n = 54

9 (17%)

28 (52%)

17 (32%)

0.91

0.95

0.39 - 2.33

  1. SNPs are not associated with clinicopathological data like metachronous development of distant metastases, gender, age (median: 66.32 years), tumor stages (pT3, pT4), lymph node status (N1 to N3: with lymph node metastases) and UICC stages. Ser: serine, Leu: leucine, Arg: arginine, Thr: threonine. P-values were determined by using Chi-Square test and odds ratios (OR) with 95% confidence intervals (95% CI) were calculated.
Back to article page

Molecular Cancer

ISSN: 1476-4598